子宫内膜癌组织中酪氨酸蛋白激酶的活性研究  

The clinical significance of study on the activity of tyrosine protein kinase in endometrial carcinoma

作　　者：罗雪莹[1] 王占平[1] 

机构地区：[1]沈阳市第一人民医院妇产科,辽宁沈阳110041

出　　处：《中国医药导报》2008年第14期23-24,共2页China Medical Herald

摘　　要：目的:通过比较子宫内膜癌、子宫内膜非典型增生及正常子宫内膜组织中蛋白酪氨酸磷酸化水平的差异,以探讨子宫内膜癌发生过程中酪氨酸蛋白激酶(TPK)活性改变的意义。方法:应用免疫组化S-P法测定40例子宫内膜癌、17例子宫内膜非典型增生、28例正常子宫内膜组织中磷酸酪氨酸蛋白(P-Tyr)的表达,从而反映3组中TPK活性水平。结果:在子宫内膜癌、子宫内膜非典型增生及正常子宫内膜组织中P-Tyr阳性表达率分别为75.00%、47.06%、14.29%,3组间差异有显著性(P<0.05)且TPK活性存在显著差异:即子宫内膜癌组高于非典型增生组和正常子宫内膜组。子宫内膜癌组织中,中、低分化组P-Tyr表达明显高于高分化组,差异有显著性(P<0.05)。结论:TPK活性异常是引起子宫内膜异常增生的原因,且与子宫内膜癌病理分化程度相关,而与临床分期、浸润程度及淋巴结转移无关。Objective： To evaluate the change of tyrosine phosphorylation status in endometrial carcinoma,atypical hyperplasia and normal endometrium, and to explore the significance of the activity of tyrosine protein kinase in the occurrence of endometrial carcinoma.Methods： Using S-P immunohistochemisty method, the expression of phosphotyrosine （P-Tyr） in the specimens of 40 cases with endometrial carcinoma,17 cases with atypical hyperplasia and 28 cases with normal endometrium were examined,thus getting the activity of tyrosine protein kinase in the three groups.Results：The positive immunostaining rate of P-Tyr in cases with endometrial carcinoma, atypical hyperplasia and normal endometrium were 75%, 47.06%, and 14.29% respectively,there was significant difference between cancer tissues, normal endometrium and atypical hyperplasia （P〈0.05）,the activity of tyrosine protein kinase in endometrial carcinoma was much higher than that in atypical hyperplasia and normal endometrium.In the endometrial carcinoma,the expression of P-Tyr in moderately-poorly differentiated was significantly higher than that in well differentiated,there was significant difference （P〈0.05）.Conclusion：The abnormal activity of tyrosine protein kinase is the cause with endometrium abnormal growth,and correlated with histological grade,but not with clinical stage,muscles invasion, lymphatic gland transfer.

关 键 词：子宫内膜肿瘤 酪氨酸蛋白激酶 磷酸酪氨酸 

分 类 号：R737.33[医药卫生—肿瘤]